ICD-11 code 2B90.30 refers to adenocarcinoma of the sigmoid colon. Adenocarcinoma is a type of cancer that begins in the glandular cells lining the inside of an organ. In this case, the cancer originates in the sigmoid colon, which is the S-shaped final section of the large intestine before the rectum.
Adenocarcinoma is the most common type of colon cancer, accounting for about 95% of all cases. It typically starts as a small, noncancerous growth called a polyp, which can eventually develop into cancer over time. Symptoms of adenocarcinoma of the sigmoid colon can include changes in bowel habits, blood in the stool, abdominal pain, and unexplained weight loss.
Treatment for adenocarcinoma of the sigmoid colon typically involves surgery to remove the cancerous tissue. Depending on the stage of the cancer, chemotherapy and radiation therapy may also be recommended. Early detection through screening tests such as colonoscopies can improve the chances of successful treatment and recovery for patients with this form of cancer.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The equivalent SNOMED CT code for the ICD-11 code 2B90.30, which represents adenocarcinoma of the sigmoid colon, is 388156008. SNOMED CT, short for Systematized Nomenclature of Medicine Clinical Terms, is a standardized system used for encoding clinical information in electronic health records. This particular code in SNOMED CT specifically identifies the presence of adenocarcinoma in the sigmoid colon within the gastrointestinal system. It allows healthcare professionals to accurately document and communicate information about this specific type of cancer using a universal terminology. By using SNOMED CT codes, healthcare providers can ensure consistency and interoperability in recording and sharing clinical data related to adenocarcinoma of the sigmoid colon.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Symptoms of 2B90.30, also known as adenocarcinoma of the sigmoid colon, may vary depending on the stage of the cancer. In the early stages, patients may not experience any symptoms at all. As the cancer progresses, common symptoms may include changes in bowel habits such as diarrhea or constipation, blood in the stool, abdominal pain, bloating, and unexplained weight loss.
Some individuals with adenocarcinoma of the sigmoid colon may also experience fatigue, weakness, and a feeling of fullness even after eating small amounts of food. Additionally, patients may notice a persistent urge to have a bowel movement even after passing stool. In some cases, the cancer may cause a blockage in the colon, leading to severe abdominal cramping, vomiting, and a distended abdomen.
It is important to note that symptoms of adenocarcinoma of the sigmoid colon can be similar to those of other gastrointestinal conditions, such as inflammatory bowel disease or hemorrhoids. Therefore, if experiencing any of these symptoms, it is crucial to seek medical evaluation to determine the underlying cause. Early detection and prompt treatment can significantly improve the prognosis for individuals with this type of cancer.
🩺 Diagnosis
The diagnosis of 2B90.30, Adenocarcinoma of the sigmoid colon, typically involves a thorough medical history review, physical examination, and various diagnostic tests. Patients may present with symptoms such as changes in bowel habits, blood in stool, abdominal pain, weight loss, and fatigue. The medical history review helps in identifying any risk factors for colorectal cancer, such as age, family history, inflammatory bowel disease, or genetic syndromes.
Physical examination may reveal signs of abdominal tenderness, palpable masses, or enlarged lymph nodes. However, physical examination alone is not sufficient for diagnosing adenocarcinoma of the sigmoid colon. Therefore, various diagnostic tests are utilized to confirm the diagnosis and stage the cancer. These tests include colonoscopy, biopsy, imaging studies (such as CT scans, MRI, or PET scans), blood tests (including tumor markers like CEA and CA 19-9), and genetic testing in some cases.
Colonoscopy is a key diagnostic tool for visually examining the sigmoid colon, obtaining tissue samples for biopsy, and removing polyps if present. Biopsy involves obtaining tissue samples from the colon for pathological analysis. The histopathological examination of the biopsy samples confirms the presence of adenocarcinoma and helps determine the tumor grade, stage, and molecular characteristics. Imaging studies play a crucial role in evaluating the extent of the cancer, detecting metastases, and planning treatment strategies. Blood tests may help in monitoring tumor burden, response to treatment, and disease recurrence. Additionally, genetic testing may be recommended for patients with a family history of colorectal cancer or suspected genetic syndromes.
💊 Treatment & Recovery
Treatment for adenocarcinoma of the sigmoid colon, classified as 2B90.30 in medical coding systems, typically involves a multidisciplinary approach. Surgical resection is often the primary treatment option for localized tumors, with the goal of removing the cancerous tissue. This may involve a partial colectomy to remove the affected portion of the colon.
In addition to surgery, patients with adenocarcinoma of the sigmoid colon may undergo chemotherapy and/or radiation therapy as part of their treatment plan. Chemotherapy may be administered before surgery (neoadjuvant therapy) to shrink the tumor, or after surgery (adjuvant therapy) to kill any remaining cancer cells. Radiation therapy may also be used to target the tumor directly or to help alleviate symptoms in cases of advanced disease.
In cases where the cancer has spread beyond the sigmoid colon to other parts of the body, treatment may focus on managing symptoms and improving quality of life. This may involve palliative care, which aims to relieve pain and discomfort without actively attempting to cure the disease. Supportive therapies such as pain management, nutrition counseling, and emotional support are often integral components of the treatment plan for advanced adenocarcinoma of the sigmoid colon.
🌎 Prevalence & Risk
In the United States, the prevalence of 2B90.30 (Adenocarcinoma of sigmoid colon) varies depending on factors such as age, gender, and genetic predisposition. According to recent studies, the overall incidence rate of sigmoid colon adenocarcinoma in the United States is approximately 4 cases per 100,000 people per year. However, this rate can be higher in certain populations, such as individuals over the age of 50 or those with a family history of colon cancer.
In Europe, the prevalence of sigmoid colon adenocarcinoma is similarly influenced by demographic and lifestyle factors. Studies have shown that the incidence rate of this type of cancer in Europe is slightly higher than in the United States, with an average of 5 cases per 100,000 people per year. Additionally, some European countries have higher rates of colon cancer overall, which may contribute to an increased prevalence of sigmoid colon adenocarcinoma in these regions.
In Asia, the prevalence of sigmoid colon adenocarcinoma is generally lower compared to Western countries like the United States and Europe. This difference may be due to a variety of factors, including differences in dietary habits, lifestyle choices, and genetic predisposition. Studies have shown that the incidence rate of sigmoid colon adenocarcinoma in Asia is approximately 3 cases per 100,000 people per year, although this rate can vary significantly between different Asian countries.
In Africa, the prevalence of sigmoid colon adenocarcinoma is not well-documented, but studies suggest that the incidence rate of this type of cancer is lower in African countries compared to Western regions like the United States and Europe. Factors such as limited access to healthcare, lower life expectancy, and differences in genetic susceptibility may contribute to the lower prevalence of sigmoid colon adenocarcinoma in Africa. Further research is needed to better understand the epidemiology of this cancer in African populations.
😷 Prevention
To prevent adenocarcinoma of the sigmoid colon, individuals should prioritize maintaining a healthy lifestyle. This includes consuming a balanced diet rich in fruits, vegetables, whole grains, and lean proteins. Regular exercise can also help reduce the risk of developing colon cancer by promoting a healthy weight and supporting proper digestion.
Another key preventive measure is to undergo regular screenings for colon cancer. This typically involves a colonoscopy, which allows healthcare providers to detect any abnormal growths in the colon and rectum at an early stage. Early detection significantly increases the chances of successful treatment and can help prevent the progression of adenocarcinoma of the sigmoid colon.
Additionally, avoiding tobacco and excessive alcohol consumption can help reduce the risk of developing colon cancer. Research has shown that smoking and heavy drinking are linked to an increased risk of various types of cancer, including colon cancer. By quitting smoking and moderating alcohol intake, individuals can minimize their risk of developing adenocarcinoma of the sigmoid colon.
🦠 Similar Diseases
Similar diseases to 2B90.30 include 2B90.31 (Adenocarcinoma of descending colon). This code specifically denotes adenocarcinoma in the descending colon, which is also a type of colorectal cancer. Adenocarcinoma is the most common type of colon cancer, characterized by the growth of malignant cells in the glandular tissue of the colon.
Another related disease is 2B90.32 (Adenocarcinoma of transverse colon). This code refers to adenocarcinoma affecting the transverse colon, which represents the middle part of the large intestine. Adenocarcinoma in this location may present with symptoms such as abdominal pain, changes in bowel habits, and unintentional weight loss.
Additionally, 2B90.33 (Adenocarcinoma of ascending colon) is another disease similar to 2B90.30. Adenocarcinoma in the ascending colon involves malignant growths in the portion of the colon located on the right side of the abdomen. Symptoms of adenocarcinoma in this region may include blood in the stool, fatigue, and a feeling of incomplete bowel emptying.